Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FOXO3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FOXO3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FOXO3_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FOXO3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/FOXO3_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FOXO3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FOXO3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FOXO3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FOXO3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FOXO3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00425935 | Stomach | GC | glucose homeostasis | 34/1159 | 258/18723 | 2.54e-05 | 7.31e-04 | 34 |
GO:00335005 | Stomach | GC | carbohydrate homeostasis | 34/1159 | 259/18723 | 2.76e-05 | 7.80e-04 | 34 |
GO:00016785 | Stomach | GC | cellular glucose homeostasis | 25/1159 | 172/18723 | 5.90e-05 | 1.35e-03 | 25 |
GO:0071384 | Stomach | GC | cellular response to corticosteroid stimulus | 13/1159 | 61/18723 | 7.41e-05 | 1.63e-03 | 13 |
GO:19037066 | Stomach | GC | regulation of hemopoiesis | 42/1159 | 367/18723 | 9.03e-05 | 1.87e-03 | 42 |
GO:00425426 | Stomach | GC | response to hydrogen peroxide | 22/1159 | 146/18723 | 9.34e-05 | 1.92e-03 | 22 |
GO:20003776 | Stomach | GC | regulation of reactive oxygen species metabolic process | 23/1159 | 157/18723 | 1.02e-04 | 2.03e-03 | 23 |
GO:00456376 | Stomach | GC | regulation of myeloid cell differentiation | 28/1159 | 210/18723 | 1.04e-04 | 2.05e-03 | 28 |
GO:0033209 | Stomach | GC | tumor necrosis factor-mediated signaling pathway | 17/1159 | 99/18723 | 1.13e-04 | 2.16e-03 | 17 |
GO:0071385 | Stomach | GC | cellular response to glucocorticoid stimulus | 12/1159 | 56/18723 | 1.32e-04 | 2.47e-03 | 12 |
GO:19032016 | Stomach | GC | regulation of oxidative stress-induced cell death | 14/1159 | 74/18723 | 1.55e-04 | 2.81e-03 | 14 |
GO:00313316 | Stomach | GC | positive regulation of cellular catabolic process | 46/1159 | 427/18723 | 1.79e-04 | 3.12e-03 | 46 |
GO:00346146 | Stomach | GC | cellular response to reactive oxygen species | 22/1159 | 155/18723 | 2.27e-04 | 3.83e-03 | 22 |
GO:00022626 | Stomach | GC | myeloid cell homeostasis | 22/1159 | 157/18723 | 2.73e-04 | 4.45e-03 | 22 |
GO:19004076 | Stomach | GC | regulation of cellular response to oxidative stress | 15/1159 | 89/18723 | 3.46e-04 | 5.47e-03 | 15 |
GO:00341016 | Stomach | GC | erythrocyte homeostasis | 19/1159 | 129/18723 | 3.68e-04 | 5.70e-03 | 19 |
GO:00098966 | Stomach | GC | positive regulation of catabolic process | 50/1159 | 492/18723 | 3.89e-04 | 5.97e-03 | 50 |
GO:00303306 | Stomach | GC | DNA damage response, signal transduction by p53 class mediator | 13/1159 | 72/18723 | 4.25e-04 | 6.35e-03 | 13 |
GO:00362936 | Stomach | GC | response to decreased oxygen levels | 36/1159 | 322/18723 | 4.36e-04 | 6.47e-03 | 36 |
GO:1903428 | Stomach | GC | positive regulation of reactive oxygen species biosynthetic process | 7/1159 | 24/18723 | 4.66e-04 | 6.83e-03 | 7 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FOXO3 | SNV | Missense_Mutation | novel | c.1165G>A | p.Asp389Asn | p.D389N | O43524 | protein_coding | tolerated(0.2) | possibly_damaging(0.644) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FOXO3 | SNV | Missense_Mutation | novel | c.1327N>A | p.Leu443Ile | p.L443I | O43524 | protein_coding | deleterious(0.01) | possibly_damaging(0.637) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
FOXO3 | SNV | Missense_Mutation | novel | c.1873N>C | p.Glu625Gln | p.E625Q | O43524 | protein_coding | deleterious(0.01) | possibly_damaging(0.616) | TCGA-AR-A0TT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
FOXO3 | insertion | Frame_Shift_Ins | novel | c.1325_1326insTGGTT | p.Leu443GlyfsTer45 | p.L443Gfs*45 | O43524 | protein_coding | | | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
FOXO3 | SNV | Missense_Mutation | novel | c.907C>A | p.Leu303Met | p.L303M | O43524 | protein_coding | tolerated(0.05) | possibly_damaging(0.898) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FOXO3 | SNV | Missense_Mutation | novel | c.1156C>A | p.Leu386Ile | p.L386I | O43524 | protein_coding | tolerated(0.18) | benign(0.232) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FOXO3 | SNV | Missense_Mutation | novel | c.730N>A | p.Gly244Arg | p.G244R | O43524 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FOXO3 | SNV | Missense_Mutation | | c.1103G>A | p.Arg368Gln | p.R368Q | O43524 | protein_coding | deleterious(0.02) | benign(0.066) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FOXO3 | SNV | Missense_Mutation | | c.968N>T | p.Arg323Leu | p.R323L | O43524 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
FOXO3 | SNV | Missense_Mutation | rs570814853 | c.1330C>T | p.Arg444Cys | p.R444C | O43524 | protein_coding | deleterious(0.04) | benign(0.021) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |